Lyra Accounts Payable from 2010 to 2025

LYRA Stock  USD 0.16  0.02  11.11%   
Lyra Therapeutics' Accounts Payable is increasing over the years with slightly volatile fluctuation. Overall, Accounts Payable is expected to go to about 2 M this year. Accounts Payable is the amount Lyra Therapeutics owes to suppliers or vendors for products or services received but not yet paid for. It represents Lyra Therapeutics' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2019-12-31
Previous Quarter
2.3 M
Current Value
1.2 M
Quarterly Volatility
1.3 M
 
Covid
Check Lyra Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lyra Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 3.1 M, Interest Income of 3.1 M or Depreciation And Amortization of 474.7 K, as well as many indicators such as Price To Sales Ratio of 8.32, Dividend Yield of 0.0 or PTB Ratio of 1.1. Lyra financial statements analysis is a perfect complement when working with Lyra Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Lyra Therapeutics Correlation against competitors.
For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.

Latest Lyra Therapeutics' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Lyra Therapeutics over the last few years. An accounting item on the balance sheet that represents Lyra Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Lyra Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Lyra Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lyra Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Lyra Accounts Payable Regression Statistics

Arithmetic Mean1,232,030
Geometric Mean996,098
Coefficient Of Variation75.73
Mean Deviation741,919
Median631,000
Standard Deviation933,031
Sample Variance870.5B
Range2.5M
R-Value0.70
Mean Square Error477.3B
R-Squared0.49
Significance0
Slope136,946
Total Sum of Squares13.1T

Lyra Accounts Payable History

2025M
20241.2 M
20233.1 M
20222.6 M
20213.1 M
2020922 K
20191.1 M

About Lyra Therapeutics Financial Statements

Lyra Therapeutics stakeholders use historical fundamental indicators, such as Lyra Therapeutics' Accounts Payable, to determine how well the company is positioned to perform in the future. Although Lyra Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Lyra Therapeutics' assets and liabilities are reflected in the revenues and expenses on Lyra Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Lyra Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable1.2 MM

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Lyra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lyra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lyra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lyra Therapeutics Stock:
Check out the analysis of Lyra Therapeutics Correlation against competitors.
For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.43)
Revenue Per Share
0.024
Quarterly Revenue Growth
0.432
Return On Assets
(0.36)
Return On Equity
(1.85)
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.